Brought to you by 
Novartis Pharma and Idenix enter antiviral deal; terminated
Mar 2003
Executive Summary
In connection with its recent purchase of a majority interest in antiviral therapeutics company Idenix Pharmaceuticals, Novartis Pharma AG has obtained rights to two of the company's oral hepatitis B drug candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis Pharma and Idenix enter antiviral deal; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice